Bioventus Inc
For the period ended Sep 28, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 28, 2024 · Filed Nov 5, 2024
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Balance Sheets as of and
Consolidated Condensed Balance Sheets as of September 28, 2024 and December 31, 2023
(Amounts in thousands, except share amounts)
| September 28, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $43,074 | $36,964 |
| Accounts receivable, net | 121,925 | 122,789 |
| Inventory | 90,032 | 91,333 |
| Prepaid and other current assets | 16,923 | 16,913 |
| Assets held for sale | 26,734 | — |
| Total current assets | 298,688 | 267,999 |
| Property and equipment, net | 29,425 | 36,605 |
| Goodwill | 7,462 | 7,462 |
| Intangible assets, net | 414,809 | 482,350 |
| Operating lease assets | 9,779 | 13,353 |
| Deferred tax assets | 7,396 | — |
| Investment and other assets | 1,933 | 3,141 |
| Total assets | $769,492 | $810,910 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $16,849 | $23,038 |
| Accrued liabilities | 128,697 | 119,795 |
| Current portion of long-term debt | 38,566 | 27,848 |
| Current portion of contingent consideration | 19,228 | — |
| Other current liabilities | 3,918 | 4,816 |
| Liabilities held for sale | 4,234 | — |
| Total current liabilities | 211,492 | 175,497 |
| Long-term debt, less current portion | 345,021 | 366,998 |
| Deferred income taxes | — | 1,213 |
| Contingent consideration | — | 18,150 |
| Other long-term liabilities | 26,146 | 27,934 |
| Total liabilities | 582,659 | 589,792 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ Equity | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued | ||
| Class A common stock, $0.001 par value, 250,000,000 shares authorized as of September 28, 2024 and December 31, 2023, 65,337,432 and 63,267,436 shares issued and outstanding as of September 28, 2024 and December 31, 2023, respectively | 65 | 63 |
| Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of September 28, 2024 and December 31, 2023 | 16 | 16 |
| Additional paid-in capital | 503,134 | 494,254 |
| Accumulated deficit | (354,922) | (321,536) |
| Accumulated other comprehensive income | 445 | 794 |
| Total stockholders’ equity attributable to Bioventus Inc. | 148,738 | 173,591 |
| Noncontrolling interest | 38,095 | 47,527 |
| Total stockholders’ equity | 186,833 | 221,118 |
| Total liabilities and stockholders’ equity | $769,492 | $810,910 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.